

August 4, 2026

|                                                                                                                                                                                                          |                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To<br>Listing Department,<br><b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b><br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br><b>MUMBAI -400 051</b><br><br><b>Company Code No. AUROPHARMA</b> | To<br>The Corporate Relations Department<br><b>BSE LIMITED</b><br>Phiroz Jeejeebhoy Towers,<br>25 <sup>th</sup> floor, Dalal Street,<br><b>MUMBAI -400 001</b><br><br><b>Company Code No. 524804</b> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir / Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, the Company has sent a letter providing a web-link of the Integrated Annual Report 2025-26 to those Members who have not registered their e-mail addresses with the Company/Depositories. A copy of the letter is enclosed for your record.

The above information is also available on the website of the Company [www.aurobindo.com](http://www.aurobindo.com)

Please take the information on record.

Thanking you,

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

Encl: as above.

**AUROBINDO PHARMA LIMITED**  
[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

**AUROBINDO PHARMA LIMITED**

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maithriviher, Ameerpet, Hyderabad - 500038, Telangana, India

Tel No. +91 40 2373 6370, 2374 7340

Corp. Office: Galaxy, Floors 22-24 Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad - 500 032, Telangana, India. Tel No.: +91 40 66725000 / 66721200

E-mail: [info@aurobindo.com](mailto:info@aurobindo.com); Website: [www.aurobindo.com](http://www.aurobindo.com)

Date: 03.08.2026

Folio No. / DP Id Client Id: APL025063

Dear Shareholder,

**Subject: Web-link of the Annual Report for the Financial Year ended March 31, 2026**

We are pleased to inform you that the 39<sup>th</sup> Annual General Meeting ("AGM") of the Members of Aurobindo Pharma Limited will be held on **Thursday, the 27<sup>th</sup> day of August 2026 at 3:30 p.m. IST** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as per the AGM Notice.

In accordance with Regulation 36 (1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the 39<sup>th</sup> AGM Notice and Integrated Annual Report of Aurobindo Pharma Limited for the financial year 2025-26 has been emailed to the shareholders whose email address has been registered with the Depository Participants / Registrar & Transfer Agent (RTA), KFin Technologies Limited.

In the absence of your email address being registered with the Depository Participant / RTA, pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, please find below the web-link to access the 39<sup>th</sup> AGM Notice and Integrated Annual Report 2025-26.

|                               |                                                                                                                                                                                                                                 |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Web-link                      | <a href="https://www.aurobindo.com/investors/disclosures-under-regulation-46/financial-information/annual-reports">https://www.aurobindo.com/investors/disclosures-under-regulation-46/financial-information/annual-reports</a> |
| Path of Annual Report 2025-26 | <a href="http://www.aurobindo.com">www.aurobindo.com</a> >>> INVESTORS >>> Results, Reports & Presentations >>> ANNUAL REPORTS >>> Annual Report 2025-26                                                                        |
| QR CODE                       |                                                                                                                                               |

As per the SEBI guidelines, it is mandatory for shareholders to update their PAN, KYC details (including postal address with pin code, email address, mobile number, bank account details), and nomination details. We request you to update your KYC details and submit the required documents/information to your respective Depository Participant / RTA at [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com) at the earliest convenience. Furthermore, any payments, including dividends, for folios where PAN or KYC details are not updated, will only be made electronically upon the registration of the required information.

We would also like to draw attention of our shareholders to 'Senior Citizens Investor Cell' which has been formed by our RTA to assist exclusively the shareholders who are senior citizens (above 60 years of age) in redressing their grievances, complaints and queries. The senior citizens wishing to avail this service can send the communication to [senior.citizen@kfintech.com](mailto:senior.citizen@kfintech.com). A dedicated toll-free number 1800 3094 006 is also provided for the convenience of senior citizens.

The following are the e-voting details

|                                                    |                                            |
|----------------------------------------------------|--------------------------------------------|
| Cut-off date to determine entitlement for e-voting | Thursday, August 20, 2026                  |
| E-voting start date and time                       | Monday, August 24, 2026 (9:00 a.m. IST)    |
| E-voting end date and time                         | Wednesday, August 26, 2026 (5:00 p.m. IST) |

You can also access the 39<sup>th</sup> AGM Notice and Integrated Annual Report 2025-26 by scanning the QR Code provided in this letter and for any other queries or further assistance, please contact our RTA at [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com).

We appreciate your prompt attention to this letter.

For any queries or further assistance, please reach out to the RTA at [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com).

**For Aurobindo Pharma Limited**

Sd/-

**B. Adi Reddy**

**Company Secretary & Compliance officer**